DZ Bank reiterated their buy rating on shares of Merck KGaA (FRA:MRK) in a research report report published on Wednesday morning, Borsen Zeitung reports.
A number of other research firms have also issued reports on MRK. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday, July 30th. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a neutral rating in a report on Friday, August 9th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a buy rating in a report on Thursday, August 8th. Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday, June 18th. Finally, UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of €100.67 ($117.05).
Shares of FRA:MRK traded down €0.38 ($0.44) during trading on Wednesday, reaching €92.96 ($108.09). The company had a trading volume of 295,845 shares. The firm’s fifty day moving average price is €93.68. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: P/E Growth (PEG)
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.